ImmunoPrecise Antibodies : Report of Voting Results - Form 6-K
January 05, 2023 at 07:58 pm
Share
Report of Voting Results
Submitted Pursuant to
Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations
In accordance with Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations, this report describes the matters voted upon and the outcome of the votes at the annual general and special meeting of shareholders of ImmunoPrecise Antibodies Ltd. (the "Company") held on December 13, 2022, at the offices of Lavery, de Billy, L.L.P., 1 Place Ville Marie, 40th Floor, Montreal, Quebec (the "Meeting"). Each of the matters is described in greater detail in the Company's management information circular dated November 11, 2022 (the "Circular").
(a)The number of directors was set at six. The following are the voting results on this matter:
FOR
% FOR
AGAINST
% AGAINST
Number of Directors
4,172,534
96.16%
166,745
3.84%
(b)In the Circular, management of the Company proposed six nominees for election as directors of the Company for the ensuing year or until their successors are duly elected or appointed. After distribution of the Circular and proxy materials, Anna K. Petterson, a nominee for re-election, notified the Company that she has accepted a position with another company and, due to a potential conflict of interest, will no longer be acting as a director of the Company. The remaining five nominees were elected. The following are the voting results on this matter:
FOR
% FOR
WITHHELD
% WITHHELD
Jennifer L. Bath
4,277,141
98.57%
62,138
1.43%
Robert D. Burke
3,891,345
89.68%
447,934
10.32%
Lisa Helbing
4,148,499
95.60%
190,780
4.40%
James Kuo
1,664,677
38.36%
2,674,602
61.64%
Gregory S. Smith
3,733,816
86.05%
605,463
13.95%
(c)Grant Thornton LLP was reappointed as the Company's auditors and the directors were authorized to fix the remuneration to be paid to the auditors. The following are the voting results on this matter:
FOR
% FOR
WITHHELD
% WITHHELD
Reappointment of Auditors
6,210,748
99.84%
9,784
0.16%
(d)The Company's 10% rolling stock option plan was approved and ratified. The following are the voting results on this matter:
FOR
% FOR
AGAINST
% AGAINST
Stock Option Plan
4,273,041
98.47%
66,238
1.53%
1
(e)The Company's shareholder rights plan was reconfirmed. The following are the voting results on this matter:
ImmunoPrecise Antibodies Ltd. published this content on 05 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 January 2023 19:57:09 UTC.
ImmunoPrecise Antibodies Ltd. is a Canada-based biotherapeutic research and technology company. It leverages systems biology, multiomics modelling and artificial intelligence systems to support its technologies in bioplatform-based antibody discovery. Its services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners to discover and develop novel biologics. It utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases. It offers services, such as immunogen design and manufacturing, B cell sorting incorporating its function-first B cell screening and sequencing, and the production and screening of custom, immune, and naive phage display libraries. It also operates LSA instrument platform, which is a provider of high-throughput large and small molecule screening and characterization solutions.
IMMUNOPRECISE ANTIBODIES LTD. 
